TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) major shareholder Lynx1 Capital Management Lp sold 25,400 shares of TScan Therapeutics stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $2.52, for a total value of $64,008.00. Following the transaction, the insider now directly owns 5,224,600 shares of the […]